• Dentsply Sirona (NasdaqGS:XRAY) expanded its partnership with Burkhart Dental Supply to distribute its full technology portfolio across the US.
• The company also announced new Board appointments, adding leaders with extensive healthcare and financial experience.

Dentsply Sirona, a global dental technology company, is leaning further into digital tools and equipment that support dentists, dental groups, and labs. By working more closely with Burkhart Dental Supply, the company is aiming to make its technology easier for practices across the US to access and purchase in one place.

At the same time, NasdaqGS:XRAY is reshaping its Board with executives who bring deep investment banking and operational finance backgrounds in healthcare. For investors, these moves relate both to how the business reaches customers and to how it is overseen at the top, which can be relevant when considering long-term positioning and execution risk.

Stay updated on the most important news stories for DENTSPLY SIRONA by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on DENTSPLY SIRONA.

The expanded Burkhart agreement pushes more of Dentsply Sirona’s digital equipment into a distributor that already has deep relationships with practices and dental groups. For you as an investor, that matters because products like CEREC systems, Primescan scanners, and advanced imaging often require education, installation, and ongoing support, which are harder to scale with a purely direct sales approach. Pairing a broader technology portfolio with Burkhart’s local service footprint may help address earlier issues in equipment volumes that contributed to recent impairment charges in the Connected Technology Solutions segment.

How This Fits Into The DENTSPLY SIRONA Narrative

• The broader distribution of digital dentistry tools through Burkhart supports the narrative focus on expanding digital platforms and closer customer relationships, which the company links to higher-margin, recurring revenue over time.
• The need to record goodwill and intangible impairments tied to Orthodontic and Implant Solutions and Connected Technology Solutions highlights that prior investments and volume expectations have not fully lined up with reality, which challenges the narrative of smooth execution on growth initiatives.
• The addition of Board members with long healthcare investment banking and CFO experience introduces a governance and capital allocation angle that is not fully reflected in the existing narrative but could shape how aggressively Dentsply Sirona pursues cost programs, M&A, or further distribution partnerships.

Knowing what a company is worth starts with understanding its story. Check out one of the top narratives in the Simply Wall St Community for DENTSPLY SIRONA to help decide what it is worth to you.

The Risks and Rewards Investors Should Consider

• ⚠️ Recent non cash impairment charges related to equipment and implant segments signal that earlier volume and forecast assumptions did not play out as expected, which raises questions about future returns on similar investments.
• ⚠️ The company reported a net loss of US$146 million in Q4 2025 and US$598 million for the full year, so profitability and execution on cost programs remain key concerns even as new partnerships are announced.
• 🎁 The Burkhart expansion, alongside existing relationships with distributors like Patterson and Benco, gives Dentsply Sirona a broader route to market for its digital tools, which could help it compete more effectively with peers such as Align Technology, Straumann, and Envista in equipment and imaging.
• 🎁 New Board members with deep healthcare deal and CFO experience may support more disciplined capital allocation and sharper oversight of restructuring, acquisitions, and the company’s push into higher-value digital workflows.

What To Watch Going Forward

From here, you will want to see whether the April 2026 Burkhart expansion translates into stronger order trends for digital systems and scanners, especially in the US, where management has previously pointed to softer demand. Monitoring how the new directors influence decisions on restructuring, cost savings, and potential bolt-on deals will also be important, particularly after the recent goodwill and intangible write downs. Finally, keep an eye on whether the 2026 net sales guidance range of US$3.5b to US$3.6b stays intact as these distribution and governance changes bed in.

To ensure you are always in the loop on how the latest news impacts the investment narrative for DENTSPLY SIRONA, head to the community page for DENTSPLY SIRONA to never miss an update on the top community narratives.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.